Seidu S, et al. - Via an updated meta-analysis of published randomised controlled trials (RCTs) and pooling individual participant data (IPD) from three trials, researchers assessed whether primary prevention of cardiovascular outcomes and all-cause mortality events by aspirin is effective and safe in people with diabetes. The included RCTs were selected from MEDLINE, Embase, Cochrane Library, and bibliographies, and involved diabetics with no known cardiovascular disease (CVD) who were administered aspirin vs placebo (or no treatment). With a median treatment duration of 5.0 years, 34,227 participants in 12 RCTs were analyzed. In diabetes, the potential benefits of aspirin in cardiovascular primary prevention were suggested in this study. As for low dose aspirin use, individualization may be required. Each individual’s baseline CVD and bleeding risk should be the basis of use of low dose aspirin.